Fundraising Fox

Juniper Genomics

6 known investors

Find your way into Juniper Genomics

Juniper Genomics provides genomic testing for IVF, including enhanced PGT-A that analyzes both DNA and RNA from a single embryo biopsy to assess chromosome status and embryo viability, and PGT-G that expands analysis across nearly the full genome from the same sample. Its products serve fertility clinicians and IVF patients making embryo selection and genetic risk decisions.

Investors · 6

Funding

SEC filings, press & company announcements

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through Juniper Genomics went on to found or lead other companies.

Competitors · 8

by search overlap
Orchid Health13 shared keywordsOrchid offers whole genome sequencing-based genetic screening of embryos during IVF as well as preconception testing for couples, analyzing DNA to identify predispositions to monogenic diseases, chromosomal abnormalities, and polygenic risks. It serves prospective parents and IVF patients, delivering reports reviewed by board-certified genetic counselors.
Genomic Prediction12 shared keywordsLifeView, operated by Genomic Prediction, offers preimplantation genetic testing (PGT) for IVF embryos, including screening for aneuploidy, monogenic disorders, structural rearrangements, and polygenic disease risk. Its tests serve fertility clinics and IVF patients to help select embryos for transfer.
Labcorp12 shared keywordsLabCorp provides diagnostic testing services and clinical trial recruitment solutions that connect patient insights to drug development for healthcare providers.
Invitae8 shared keywordsInvitae provides genetic testing services to patients and clinicians across the United States, offering broad test offerings and genetic counseling to inform health decisions at every stage of life. Now part of Labcorp, the company leverages a nationwide network of patient service centers and coverage by most health plans to make genetic testing more accessible.
Nucleus Genomics8 shared keywordsNucleus provides genetic testing and analysis for couples planning pregnancy, screening for over 200 hereditary diseases, traits, and health conditions. For those undergoing IVF, the company offers embryo selection guidance to reduce disease risk and optimize traits including eye color, height, and intelligence.
Myriad7 shared keywordsMyriad provides germline and tumor genomic testing across hereditary cancer, prenatal and reproductive health, prostate cancer, and pharmacogenomics for mental health medications. It supplies patients and healthcare providers with genetic screening results and AI-derived insights to inform diagnosis, risk assessment, and treatment decisions.
NeoGenomics6 shared keywordsNeoGenomics develops diagnostic tests and tools for cancer care, including tests for immunotherapy response monitoring, therapy selection, and minimal residual disease detection.
Progyny6 shared keywordsProgyny provides employer-sponsored women's health and family-building benefits, covering preconception, fertility, pregnancy and postpartum, and menopause/midlife care through concierge support, digital tools, and a managed network of specialists. It serves organizations looking to offer these benefits to their workforce across the United States.

Companies competing with Juniper Genomics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Frequently asked questions

What does Juniper Genomics do?
Juniper Genomics provides genomic testing for IVF, including enhanced PGT-A that analyzes both DNA and RNA from a single embryo biopsy to assess chromosome status and embryo viability, and PGT-G that expands analysis across nearly the full genome from the same sample. Its products serve fertility clinicians and IVF patients making embryo selection and genetic risk decisions.
Who are Juniper Genomics's investors?
Juniper Genomics's investors include Amboy Street Ventures, Dria Ventures, Blue Collective, Company Ventures, Innospark Ventures, MBX Capital.